| A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn’s Disease |
Ongoing |
Guselkumab |
3 |
CNTO1959CRD3005 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam), King Saud Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| A prospective observational international study of cabozantinib tablets in combination with nivolumab as first-line treatment of advanced renal cell carcinoma in adults |
Ongoing |
Cabozantinib |
4 |
CLIN-60000 |
King Abdulaziz Medical City NG (Riyadh) |
| A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared with Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patients with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) |
Ongoing |
UX007/triheptanoin, Medium-chain Triglycerides (MCT),Dextrose. Monosaccharide. Blood Glucose-Elevating Agents. |
3 |
UX007-CL30 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A non-interventional, multinational,observational study with isatuximabin patients with relapsed and/orrefractory multiple myeloma (RRMM) |
Ongoing |
SARCLISA® ( isatuximab - irfc ) |
4 |
OBS16577 |
Mouwasat Hospital (Dammam),King Faisal Specialist Hospital and Research Center (Jeddah),King Abdulaziz Medical City NG (Jeddah),King Abdulaziz Medical City NG (Riyadh) |
| A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum |
Ongoing |
Hydrocortisone Acetate 90 mg |
3 |
CHS1221 |
King Abdulaziz Medical City NG (Jeddah),King Abdulaziz University Hospital (Jeddah),King Fahad Medical City (Riyadh) |
| International collaborative treatment protocol for infants under one year with KMT2Arearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia (Interfant-21) |
Ongoing |
BLINATUMOMAB |
3 |
SCT22R/016/12 |
King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Medical City NG (Jeddah) |
| A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB |
Rejected |
ATEZOLIZUMAB, SORAFENIB |
3 |
MO42541 |
King Abdulaziz Medical City NG (Riyadh) |
| An Open label, Single Center, prospective interventional, phase II clinical trial to evaluate the Efficacy and Safety of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine(BV-AVD) combination escalation in advanced stage classical Hodgkin lymphoma patients who did not achieve interim Positron Emission Tomography (PET2) negativity (defined as Deauville score 3 or less) after 2 cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) |
Rejected |
BRENTUXIMAB VEDOTIN, DACARBAZINE, VINBLASTINE, DOXORUBICIN HYDROCHLORIDE |
2 |
1 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3) |
Ongoing |
Lenvatinib (Lenvima) + Durvalumab (Imfinzi) + Tremelimumab (Imjudo) |
3 |
D910VC00001 |
King Faisal Specialist Hospital and Research Center (Riyadh) ,King Abdulaziz Medical City NG (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh) |
| A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA) |
Ongoing |
Tozorakimab (MEDI3506) |
3 |
D9185C00001 |
King Abdulaziz Medical City NG (Jeddah), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
